|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumors of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wen PY and DeAngelis LM: Chemotherapy for
low-grade gliomas: Emerging consensus on its benefits. Neurology.
68:1762–1763. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong ET, Hess KR, Gleason MJ, Jaeckle KA,
Kyritsis AP, Prados MD, Levin VA and Yung WK: Outcomes and
prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol. 17:2572–2578. 1999.PubMed/NCBI
|
|
7
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Folkman J: Tumor angiogenesis: T
herapeutic implications. N Engl J Med. 285:1182–1186. 1971.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siemann DW and Shi W: Targeting the tumor
blood vessel network to enhance the efficacy of radiation therapy.
Semin Radiat Oncol. 13:53–61. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miletic H, Niclou SP, Johansson M and
Bjerkvig R: Anti-VEGF therapies for malignant glioma, Treatment
effects and escape mechanisms. Expert Opin Ther Targets.
13:455–468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Beal K, Abrey LE and Gutin PH:
Antiangiogenic agents in the treatment of recurrent or newly
diagnosed glioblastoma, Analysis of single-agent and combined
modality approaches. Radiat Oncol. 6:22011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gilbert MR, Dignam JJ, Armstrong TS, Wefel
JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S,
Won M, et al: A randomized trial of bevacizumab for newly diagnosed
glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chinot OL, Wick W, Mason W, Henriksson R,
Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea
D, et al: Bevacizumab plus radiotherapy-temozolomide for newly
diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gil-Gil MJ, Mesia C, Rey M and Bruna J:
Bevacizumab for the treatment of glioblastoma. Clin Med Insights
Oncol. 7:123–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu JF, Bruno R, Eppler S, Novotny W, Lum B
and Gaudreault J: Clinical pharmacokinetics of bevacizumab in
patients with solid tumors. Cancer Chemother Pharmacol. 62:779–786.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Specenier P: Bevacizumab in glioblastoma
multiforme. Expert Rev Anticancer Ther. 12:9–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong ET, Gautam S, Malchow C, Lun M, Pan E
and Brem S: Bevacizumab for recurrent glioblastoma multiforme, A
meta-analysis. J Natl Compr Canc Netw. 9:403–407. 2011.PubMed/NCBI
|
|
21
|
Stark-Vance V: Bevacizumab and CPT-11 in
the treatment of relapsed malignant glioma. Neuro Oncol.
7:3692005.
|
|
22
|
Vredenburgh JJ, Desjardins A, Herndon JE
II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S,
Gururangan S, Wagner M, et al: Phase II trial of bevacizumab and
irinotecan in recurrent malignant glioma. Clin Cancer Res.
13:1253–1259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vredenburgh JJ, Desjardins A, Herndon JE
II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S,
Gururangan S, Sampson J, et al: Bevacizumab plus irinotecan in
recurrent glioblastoma multiforme. J Clin Oncol. 25:4722–4729.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Desjardins A, VJ, Reardon DA, Herndon JE,
Marcello J, Peters K, Gururangan S, Sathornsumetee S, Rich JN and
Friedman HS: Long-term survival from the initial trial of
bevacizumab and irinotecan. J Clin Oncol. 28(15 Suppl):
1912010.PubMed/NCBI
|
|
25
|
Friedman HS, Prados MD, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, et al: Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cloughesy T, VJ, Day B, Das A and Friedman
HS: The BRAIN Investigators: Updated safety and survival of
patients with relapsed glioblastoma treated with bevacizumab in the
BRAIN study. J Clin Oncol. 28(15 Suppl): 181s2010.
|
|
27
|
Kreisl TN, Kim L, Moore K, Duic P, Royce
C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al:
Phase II trial of single-agent bevacizumab followed by bevacizumab
plus irinotecan at tumor progression in recurrent glioblastoma. J
Clin Oncol. 27:740–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cohen MH, Shen YL, Keegan P and Pazdur R:
FDA drug approval summary, Bevacizumab (Avastin) as treatment of
recurrent glioblastoma multiforme. Oncologist. 14:1131–1138. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chamberlain MC and Johnston SK: Salvage
therapy with single agent bevacizumab for recurrent glioblastoma. J
Neurooncol. 96:259–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raizer JJ, Grimm S, Chamberlain MC,
Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J
and Bredel M: A phase 2 trial of single-agent bevacizumab given in
an every-3-week schedule for patients with recurrent high-grade
gliomas. Cancer. 116:5297–5305. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kreisl TN, Zhang W, Odia Y, Shih JH,
Butman JA, Hammoud D, Iwamoto FM, Sul J and Fine HA: A phase II
trial of single-agent bevacizumab in patients with recurrent
anaplastic glioma. Neuro Oncol. 13:1143–1150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nagane M, Nishikawa R, Narita Y, Kobayashi
H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y,
et al: Phase II study of single-agent bevacizumab in Japanese
patients with recurrent malignant glioma. Jpn J Clin Oncol.
42:887–895. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hofer S, Elandt K, Greil R, Hottinger AF,
Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, et
al: Clinical outcome with bevacizumab in patients with recurrent
high-grade glioma treated outside clinical trials. Acta Oncol.
50:630–635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang G, Huang S and Wang Z: A
meta-analysis of bevacizumab alone and in combination with
irinotecan in the treatment of patients with recurrent glioblastoma
multiforme. J Clin Neurosci. 19:1636–1640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Balañá C, Etxaniz O, Bugés C and Martínez
A: Approval denied by the european medicines agency (EMA) for
bevacizumab in the treatment of high-grade glioma recurrence A good
idea or a grave error? Clin Transl Oncol. 13:209–210. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lai A, Tran A, Nghiemphu PL, Pope WB,
Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, et al:
Phase II study of bevacizumab plus temozolomide during and after
radiation therapy for patients with newly diagnosed glioblastoma
multiforme. J Clin Oncol. 29:142–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Narayana A, Gruber D, Kunnakkat S,
Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P and Gruber ML: A
clinical trial of bevacizumab, temozolomide and radiation for newly
diagnosed glioblastoma. J Neurosurg. 116:341–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vredenburgh JJ, Desjardins A, Reardon DA,
Peters KB, Herndon JE II, Marcello J, Kirkpatrick JP, Sampson JH,
Bailey L, Threatt S, et al: The addition of bevacizumab to standard
radiation therapy and temozolomide followed by bevacizumab,
temozolomide and irinotecan for newly diagnosed glioblastoma. Clin
Cancer Res. 17:4119–4124. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vredenburgh JJ, Desjardins A, Kirkpatrick
JP, Reardon DA, Peters KB, Herndon JE II, Marcello J, Bailey L,
Threatt S, Sampson J, et al: Addition of bevacizumab to standard
radiation therapy and daily temozolomide is associated with minimal
toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat
Oncol Biol Phys. 82:58–66. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Armstrong TS, Wen PY, Gilbert MR and
Schiff D: Management of treatment-associated toxicites of
anti-angiogenic therapy in patients with brain tumors. Neuro Oncol.
14:1203–1214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Norden AD, Young GS, Setayesh K,
Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B,
Drappatz J, et al: Bevacizumab for recurrent malignant gliomas:
Efficacy, toxicity and patterns of recurrence. Neurology.
70:779–787. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gilbert MR, Wang M, Aldape K, Lassman A,
Sorenson AG, Mikkelson T, Groves M, Wener-Wasik M, Regine W and
Mehta M: RTOG 0625: A phase II study of bevacizumab with irinotecan
in recurrent glioblastoma (GBM). J Clin Oncol. 27(Suppl 15):
89s2009.
|
|
43
|
Gil MJ, de Las Peñas R, Reynés G, Balañá
C, Peréz-Segura P, García-Velasco A, Mesia C, Gallego O,
Fernández-Chacón C, Martínez-García M, et al: Bevacizumab plus
irinotecan in recurrent malignant glioma shows high overall
survival in a multicenter retrospective pooled series of the
Spanish neuro-oncology research group (GEINO). Anticancer Drugs.
23:659–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zuniga RM, Torcuator R, Jain R, Anderson
J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy, safety
and patterns of response and recurrence in patients with recurrent
high-grade gliomas treated with bevacizumab plus irinotecan. J
Neurooncol. 91:329–336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Quant EC, Norden AD, Drappatz J,
Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S and Wen
PY: Role of a second chemotherapy in recurrent malignant glioma
patients who progress on bevacizumab. Neuro Oncol. 11:550–555.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gurevich F and Perazella MA: Renal effects
of anti-angiogenesis therapy: Update for the internist. Am J Med.
122:322–328. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhu X, Wu S, Dahut WL and Parikh CR: Risks
of proteinuria and hypertension with bevacizumab, an antibody
against vascular endothelial growth factor, Systematic review and
meta-analysis. Am J Kidney Dis. 49:186–193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wu S, Kim C, Baer L and Zhu X: Bevacizumab
increases risk for severe proteinuria in cancer patients. J Am Soc
Nephrol. 21:1381–1389. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rahmathulla G, Hovey EJ, Hashemi-Sadraei N
and Ahluwalia MS: Bevacizumab in high-grade gliomas, A review of
its uses, toxicity assessment, and future treatment challenges.
Onco Targets Ther. 6:371–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Poulsen HS, Grunnet K, Sorensen M, Olsen
P, Hasselbalch B, Nelausen K, Kosteljanetz M and Lassen U:
Bevacizumab plus irinotecan in the treatment patients with
progressive recurrent malignant brain tumors. Acta Oncol. 48:52–58.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Raval SHS and Dorsett L: Bevacizumab and
irinotecan in patients (pts) with recurrent glioblastoma multiforme
(GBM). J Clin Oncol. 25(Suppl 18): 20782007.PubMed/NCBI
|
|
52
|
Bokstein F, Shpigel S and Blumenthal DT:
Treatment with bevacizumab and irinotecan for recurrent high-grade
glial tumors. Cancer. 112:2267–2273. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Taillibert S, Hoang-Xuan K, Barrie M, Guiu
S, Chauffert B, Cartalat-Carel S, Taillandier L, Fabbro M, Laigre
M, Guillamo JS, et al: ANOCEF group: Bevacizumab (B) with
irinotecan (I) in recurrent glioblastoma (GBM): A national
retrospective cohort of the ANOCEF (Association Des
Neuro-Oncologues D'Expression Française) group. Neuro Oncol.
12((Suppl 4)): iv52–iv53. 2010.
|
|
54
|
Keyrouz VF, Elias E, Chahine GY, Comair
YG, Dimassi H and Kamar FG: Updated results of a phase II trial of
bevacizumab and irinotecan in relapsed high-grade glioma. Neuro
Oncol. 12(Suppl 3): iii472010.
|
|
55
|
Pope WB, Lai A, Nghiemphu P, Mischel P and
Cloughesy TF: MRI in patients with high-grade gliomas treated with
bevacizumab and chemotherapy. Neurology. 66:1258–1260. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nghiemphu PL, Liu W, Lee Y, Than T, Graham
C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, et al:
Bevacizumab and chemotherapy for recurrent glioblastoma: A
single-institution experience. Neurology. 72:1217–1222. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Desjardins A, Reardon DA, Coan A, Marcello
J, Herndon JE II, Bailey L, Peters KB, Friedman HS and Vredenburgh
JJ: Bevacizumab and daily temozolomide for recurrent glioblastoma.
Cancer. 118:1302–1312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Verhoeff JJ, Lavini C, van Linde ME,
Stalpers LJ, Majoie CB, Reijneveld JC, van Furth WR and Richel DJ:
Bevacizumab and dose-intense temozolomide in recurrent high-grade
glioma. Ann Oncol. 21:1723–1727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Soffietti R, Trevisan E, Ruda R, Bertero
L, Bosa C, Fabrini MG and Lolli I: Phase II trial of bevacizumab
with fotemustine in recurrent glioblastoma, Final results of a
multicenter study of AINO (Italian Association of Neuro-oncology).
J Clin Oncol. 29:2011.PubMed/NCBI
|
|
60
|
Trevisan E, Ruda R, Picco E, Crasto Greco
S, Caroli M, Fabrini A, Scotti V, Lolli I, Guarneri D and Soffietti
R: Bevacizumab and fotemustine as salvage therapy in recurrent
glioblastoma, A phase II multicenter Italian study. Neuro Oncol.
12((Suppl 3)): iii49–iii50. 2010.
|
|
61
|
Hasselbalch B, Lassen U, Hansen S,
Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT
and Poulsen HS: Cetuximab, bevacizumab, and irinotecan for patients
with primary glioblastoma and progression after radiation therapy
and temozolomide, A phase II trial. Neuro Oncol. 12:508–516.
2010.PubMed/NCBI
|
|
62
|
Shapiro LQ, Beal K, Goenka A, Karimi S,
Iwamoto FM, Yamada Y, Zhang Z, Lassman AB, Abrey LE and Gutin PH:
Patterns of failure after concurrent bevacizumab and
hypofractionated stereotactic radiation therapy for recurrent
high-grade glioma. Int J Radiat Oncol Biol Phys. 85:636–642. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sathornsumetee S, Desjardins A,
Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A,
Hamilton M, Rich JN, Norfleet JA, et al: Phase II trial of
bevacizumab and erlotinib in patients with recurrent malignant
glioma. Neuro Oncol. 12:1300–1310. 2010.PubMed/NCBI
|
|
64
|
Niyazi M, Ganswindt U, Schwarz SB, Kreth
FW, Tonn JC and Geisler J: laF ougère C, Ertl L, Linn J, Siefert A
and Belka C: Irradiation and bevacizumab in high-grade glioma
retreatment settings. Int J Radiat Oncol Biol Phys. 82:67–76. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hundsberger T, Brügge D, Putora PM, Weder
P, Weber J and Plasswilm L: Re-irradiation with and without
bevacizumab as salvage therapy for recurrent or progressive
high-grade gliomas. J Neurooncology. 112:133–139. 2013. View Article : Google Scholar
|
|
66
|
Gutin PH, Iwamoto FM, Beal K, Mohile NA,
Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J and Abrey LE:
Safety and efficacy of bevacizumab with hypofractionated
stereotactic irradiation for recurrent malignant gliomas. Int J
Radiat Oncol Biol Phys. 75:156–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hainsworth JD, Shih KC, Shepard GC,
Tillinghast GW, Brinker BT and Spigel DR: Phase II study of
concurrent radiation therapy, temozolomide and bevacizumab followed
by bevacizumab/everolimus as first-line treatment for patients with
glioblastoma. Clin Adv Hematol Oncol. 10:240–246. 2012.PubMed/NCBI
|
|
68
|
Herrlinger U, Schafer N, Steinbach JP,
Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Stockhammer F,
Ringel F, Braun C, et al: Bevacizumab, irinotecan and radiotherapy
versus standard temozolomide and radiotherapy in newly diagnosed,
MGMT non-methylated glioblastoma patients: Updated results from the
randomized multicenter GLARIUS trial. European J Cancer.
49:S7742013.
|
